Times shown are in EST

9:00 am Coffee & Networking

9:20 am Chairman’s Opening Remarks

Keynote Clinical Case Studies

9:30 am Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine


• Neoantigen-directed immunotherapy has been developed using high quality machine learning-enabled prediction of neoantigens plus viral vector-based delivery of select individualized neoantigens to patients with advanced solid tumors
• A phase 1/2 trial has been conducted in the US/Australia to assess safety, immunogenicity and efficacy of this approach
• Clinical data with up to a year of follow-up, with a focus on colorectal cancer, will be presented

10:00 am Treos’ Novel & Potentially Transformative Big Data Approach to Increasing the Effectiveness of Cancer Vaccines by Incorporating a Systematic Understanding of Antigen Targets & HLA Responses


• Treos’ approach to producing two families of off-the-shelf personalized cancer vaccines
• Clinical data supporting the utility of the Treos approach
• A systematic approach to creating the future of cancer vaccines

10:30 am Personalized Cancer Vaccine for Treating Patients With Advanced Hepatocellular Cancer


• GT-EPIC™ DNA plasmid product designed and manufactured for each patient based on their tumor specific neoantigens
• Discuss the interim clinical safety and efficacy data from the first 10 patients treated on study
• The use of immuno-monitoring to assess the potency of the personalized cancer vaccine and mechanism of action of the targeted neoantigens in the clinic.

11:00 am Industry Leader’s Fireside Chat


An executive panel discussion from the C-level leaders of the field to set the scene on neoantigen based therapy development.

11:30 am Morning Break & Group Networking

Reimagining Clinical Trial Design to Show True Efficacy of Neoantigen Therapy

12:00 pm Optimizing Patient Selection & Stratification to Improve Success in Clinical Trials


• What should the patient cohort selection look like to give best chance of success?
• Which clinical end points to be selected to assess anti-tumor efficacy?
• How can the late stage product manufacturing process look like for neoantigen programs?

12:30 pm Developing mab Therapies From Tumor Neoantigens


• Monoclonal abs from Tumor antigens were charactered for specificity and antitumor function
• Identity of neo-epitopes were characterized
• Antibody functions were characterized for clinical trial development

1:00 pm Drug product manufacturing for personalized medicines


Personalized neoantigen cancer immunotherapies present unique manufacturing challenges related to scale and automation. John will share key considerations for manufacturing individualized drug products, including:

  • Accelerating commercialization by scaling out using standardized technologies
  • Automating aseptic processing within closed systems
  • Creating a supporting ecosystem for filtration, container / closure and visual inspection

1:30 pm Lunch & Networking

Establishing an Adjuvant Approach for Greater Clinical Outcomes

Establishing an Adjuvant Approach for Greater Clinical Outcomes

2:00 pm The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged


  • Exploring the use of a cell-based, allogeneic, immune primer for recruitment and activation of cross-presenting DCs
  • Harnessing skin-resident memory CD8+ T cells for adaptive immune responses

2:30 pm Overcoming Challenges for Effective Cancer Vaccine Therapy


  • Improving vaccine activity by combining with RNA encoded cytokines
  • Novel treatments to overcome immune escape via MHC I loss

3:00 pm Panel Discussion: Exploring the Bestin-Class Adjuvant to Improve Patient Response to Neoantigen Therapy


  • Discussing the best approach to turn the ‘cold tumor’ into a ‘hot tumor’.
  • Outlining the variety of neoadjuvant methods to prime immune responses to neoantigen vaccination
  • Exploring the potential of a mRNA adjuvant if an mRNA vaccine platform is used for neoantigen delivery

Addressing Manufacturing Challenges to Decrease Process & Release Times for Neoantigen Therapeutic Development

2:00 pm Optimizing Release Testing for Faster Turnaround Time to Patients In Critical Need


  • Novel and innovative methods to ensure release of safe products in a faster manner
  • Implementation of quality controls assays at each scale up step
  • Developing more flexible, risk based approach to release testing to allow for conditional release

2:30 pm Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps


  • Discussing strategy for producing cancer vaccines on an industrial scale under GMP conditions
  • Exploring how companies have handled the low availability of raw materials (DNA vectors/ viral vectors) due to priority of Covid-19 for manufacturers
  • Assessing the best strategy to deal with the logistical manufacturing issues that have arisen due to the pandemic
  • Providing insight into different bio-manufacturing timelines, clinical readiness and capacity post-pandemic

3:00 pm Roundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field

3:30 pm Afternoon Break

Looking Outside of Oncology: Examining the Use of Vaccine Platforms in Infectious Disease & Beyond

4:00 pm PeptiVAX, a Vaccine Platform for Flexibly Targeting New & Emerging Infectious Disease


• PeptiVAX is a platform based on peptide antigen coating of nonreplicating adenovirus for delivery of peptide vaccination in infectious diseases.
• Costly and time-consuming genetic engineering of new vaccines to emerging infectious diseases is not required
• A pancoronavirus vaccine strategy targeting existing and emerging strains of coronavirus utilizing novel antigens will be described

4:30 pm Targeting Antigens to Antigen Presenting Cells To Create More Efficacious Vaccines


• Vaccibody’s 3 modular format optimized for induction of rapid, strong and broad immune responses
• Targeting neoantigens to chemokine receptors on APC for induction of strong and broad CD8 T cell responses
• Combinations and applicability within personalized and off-the shelf cancer vaccines and beyond

5:00 pm Chairman’s Closing Remarks

5:15 pm Close of Summit